Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

Jan 12 (Reuters) - AbbVie said on ‌Monday ​that it has ‌struck a three-year deal with U.S. ​President Donald Trump's ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of ...

AbbVie (ABBV) has reached a three-year deal with the Trump administration to reduce drug prices and invest $100 billion in ...

North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in ...

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

As prescription drug prices in the US continue to rise, political leaders across administrations, including recently US ...

AbbVie has reached a deal with Trump administration to join TrumpRx, a direct-to-patient platform with a goal to drug prices ...

AbbVie ABBV announced that it has signed an agreement with the Trump administration to lower drug prices in the United States ...